CLVS
:NASDAQ

Add to watchlist
$2.71
Last updated:01/14/2022
CLVS: NASDAQ
$2.71
Clovis Oncology Inc

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic c…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 1 ETFs that include this stock
Company value
Market capitalization
Small (0.33B)